Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Cash flows from operating activities:
Net loss	$ (2,479)	$ (10,650)
Adjustments to reconcile to net cash provided by (used in) operating activities:
Stock-based compensation expense	5,425	5,150
Depreciation and amortization	4,909	4,514
Deferred income taxes	4,080	3,129
Non-cash development expenses from joint ventures	3,632	3,348
Change in fair value of contingent value rights	(3,005)	1,408
Impairment of in-process research and development	9,600	0
Impairment of long-lived assets	0	193
Excess tax benefits from stock-based compensation	1,247	(1,786)
Other	(55)	43
Changes in operating assets and liabilities:
Accounts receivable	27,338	(7,937)
Inventories	(1,347)	(4,540)
Income taxes	(2,163)	(8,408)
Prepaid expenses and other assets	888	1,401
Accounts payable	(7,068)	(1,143)
Accrued expenses and other liabilities	488	3
Accrued compensation	(6,900)	(10,160)
Deferred revenue	142	(3,973)
Net cash provided by (used in) operating activities	34,732	(29,408)
Cash flows from investing activities:
Purchases of property, plant and equipment	(30,921)	(16,795)
Proceeds from sale of assets	11,765	0
Proceeds from maturity of investments	1,966	2,250
Purchase of investments	0	(5,269)
Net cash used in investing activities	(17,190)	(19,814)
Cash flows from financing activities:
Proceeds from borrowings on long-term indebtedness	11,413	0
Issuance of common stock subject to exercise of stock options	401	8,695
Excess tax benefits from stock-based compensation	(1,247)	1,786
Principal payments on long-term indebtedness and line of credit	(8,670)	(8,123)
Contingent value right payment	(1,748)	0
Release of restricted cash deposit	220	0
Net cash provided by (used in) financing activities	369	2,358
Effect of exchange rate changes on cash and cash equivalents	31	(61)
Net increase (decrease) in cash and cash equivalents	17,942	(46,925)
Cash and cash equivalents at beginning of period	143,901	169,019
Cash and cash equivalents at end of period	$ 161,843	$ 122,094